Pelthos Therapeutics to acquire Castle Creek Biosciences in gene therapy merger backed by $57.5m financing

Pelthos Therapeutics Inc. (NYSE American: PTHS) has agreed to acquire Castle Creek Biosciences Inc. in a stock-based merger that would expand its dermatology business into late-stage gene-modified cell therapy, while introducing substantial contingent payments and potential shareholder dilution. Announced on October 30, 2026, the transaction provides Castle Creek shareholders with 5.2 million Pelthos common shares at closing, potential additional consideration of up to 5.8 million shares following regulatory approval of its lead therapy, and as much as $300 million in clinical and commercial milestone payments. A separate financing agreement targets at least $57.5 million in investment commitments, partly involving the conversion or cancellation of existing bridge obligations, to support the combined business and address selected liabilities. The proposed merger would add D-Fi, an investigational treatment for dystrophic epidermolysis bullosa, to Pelthos’ existing portfolio of approved dermatology products. However, the combination remains subject to closing conditions, while its eventual commercial value depends heavily on clinical development, regulatory approval and the cost of financing the enlarged business.

The transaction has produced a significant market reaction. Pelthos shares were quoted at approximately $11.11 at 10:55 a.m. Eastern Time on October 30, down 32.84% from the previous close of $16.54. The decline coincided with the announcement and its associated financing disclosures, although the available evidence does not establish how much of the movement was attributable to individual transaction terms.

The central investment tension extends beyond the potential value of Castle Creek’s gene therapy platform. Pelthos is combining an existing commercial drug franchise with a development-stage asset whose future could involve meaningful clinical expenditure, regulatory uncertainty and substantial payments to the acquired business’s former owners. The financing structure may provide additional resources, but it also creates new questions about the ownership and economic participation of existing common shareholders.

How is the Pelthos Therapeutics and Castle Creek Biosciences merger structured?

Under the definitive merger agreement signed on October 30, Castle Creek will become part of Pelthos through a two-step corporate transaction. The combined organisation will continue operating under the Pelthos Therapeutics name and retain its listing on the NYSE American under PTHS.

Castle Creek shareholders will receive 5.2 million Pelthos common shares at closing. According to the accompanying regulatory filing, those shares are expected to represent approximately 32.5% of the combined company’s fully diluted equity immediately after the initial merger, before the related private financing and excluding contingent shares. Existing Pelthos securityholders would represent approximately 67.5% on the same specified basis.

Those percentages are not a final post-financing ownership structure. The planned preferred share financing, associated warrants and potential future acquisition consideration may change the eventual share distribution. Investors should therefore distinguish the initial merger ownership allocation from the fully diluted capital structure that could emerge after subsequent conversions and milestone-related issuances.

The transaction has received approval from both companies’ boards. Pelthos shareholders representing approximately 56.2% of voting power have also approved the relevant share issuances through written consent, eliminating the need for an additional Pelthos shareholder vote on those matters.

Completion nevertheless remains conditional on several requirements, including Castle Creek shareholder approval, effectiveness of the relevant registration statement, applicable regulatory processes and the related financing arrangements. Management expects the merger to close by the end of the first quarter of 2027.

Scott Plesha will remain chief executive officer of the combined business, while Peter Greenleaf is expected to become executive chair. The proposed board will have 10 members, including two designated by Castle Creek.

Why could Castle Creek shareholders receive another 5.8 million Pelthos shares after the merger?

The initial 5.2 million-share consideration represents only the first component of the acquisition agreement.

Castle Creek shareholders may receive an additional 5.8 million common shares if D-Fi obtains approval from the US Food and Drug Administration by March 31, 2036. The additional issuance is subject to contractual adjustments, including reductions linked to the timing of approval and certain contingent expenses.

The filing specifies that the contingent share amount begins declining by 5% for each complete calendar quarter after March 31, 2031, if approval occurs after that date and before the final eligibility deadline. Consequently, the headline figure of 5.8 million additional shares should be regarded as a maximum rather than an automatic future issuance.

Together, the initial and maximum contingent acquisition consideration could reach 11 million common shares, excluding securities associated with the separate financing. However, the full amount would depend on satisfaction of the relevant conditions and cannot be treated as currently issued equity.

The transaction also establishes up to $300 million in clinical and commercial milestone payments.

The first $50 million is tied to a specified D-Fi clinical milestone that must be achieved by June 30, 2029. A further $50 million becomes payable upon the treatment’s first US commercial sale, subject to the agreement.

Additional payments are linked to D-Fi net sales reaching specified trailing twelve-month thresholds. These include $50 million when sales first reach $100 million, $75 million at $250 million and another $75 million at $500 million.

This structure aligns a substantial portion of the consideration with development and commercial achievements. It limits immediate payment obligations relative to an entirely upfront cash acquisition, but successful clinical development and commercial expansion could result in meaningful future liabilities.

Certain milestone payments may also involve shares rather than entirely cash consideration where required to preserve the intended tax treatment of the merger, subject to contractual restrictions.

What does the $57.5 million private financing actually provide to the combined company?

The merger is accompanied by a securities purchase agreement involving Ligand Pharmaceuticals Incorporated, Nomis Bay Ltd., Marshman Fund Trust II and other investors.

The initial financing arrangement provides for approximately $57.5 million through the purchase of 57,500 Series B convertible preferred shares and associated warrants. Each preferred share has a stated value of $1,000, while the accompanying warrants initially cover an aggregate of 496,951 common shares.

Additional participation could expand the financing. A designated investor has an option to purchase further preferred securities and warrants, while certain existing Castle Creek investors may participate through additional subscriptions.

The filing describes a maximum potential financing size of $80 million, including bridge financing arrangements. That amount should not be interpreted as $80 million of additional unrestricted cash available to the combined company.

Some investor obligations may be satisfied through the transfer or cancellation of existing Castle Creek bridge notes. Consequently, the transaction can involve the settlement of existing financing claims alongside the contribution of new cash.

The financing is expected to close immediately before the merger becomes effective. Pelthos intends to use the proceeds to repay certain Castle Creek indebtedness and support working capital and general corporate purposes.

The preferred securities introduce another potential source of common share dilution. Holders may convert the Series B preferred stock into common shares under the contractual terms, while the warrants create additional possible share issuance following the applicable exercise period.

These securities should not be counted as ordinary shares already outstanding. Their eventual impact depends on conversion, exercise and the rights attached to the instruments.

For existing shareholders, the relevant issue is the relationship between new capital and the ownership surrendered to obtain it. The financing could strengthen the company’s ability to pursue the enlarged development programme, but its economic benefit must eventually justify the additional claims on shareholder value.

Why is D-Fi central to the commercial rationale for the Castle Creek acquisition?

Castle Creek’s principal asset is D-Fi, also known as dabocemagene autoficel or FCX-007, an investigational gene-modified autologous cell therapy being developed for dystrophic epidermolysis bullosa.

The condition is a rare inherited skin disorder associated with mutations in the COL7A1 gene, which can impair production of functional type VII collagen. Patients can experience fragile skin, recurrent wounds and other serious complications because of abnormalities affecting the connection between skin layers.

D-Fi is designed to use a patient’s own dermal fibroblasts, modified outside the body to express type VII collagen. The genetically modified cells are then administered locally through intradermal injections into affected areas.

Castle Creek is investigating a treatment approach involving repeat administration approximately every two months. The intended mechanism could provide an additional therapeutic option for patients with persistent wounds, although clinical efficacy and safety must be established through the relevant development programme.

D-Fi has received several regulatory designations, including Orphan Drug Designation for dystrophic epidermolysis bullosa and Fast Track, Rare Pediatric Disease and Regenerative Medicine Advanced Therapy designations for its development in recessive dystrophic epidermolysis bullosa.

These designations may support aspects of regulatory development, but they do not constitute marketing approval or establish that the treatment will succeed in its remaining trials.

Castle Creek is preparing to advance its Phase 3 programme, including further evaluation of D-Fi in patients with dystrophic epidermolysis bullosa. Its development history includes registered clinical studies investigating wound-healing outcomes under controlled conditions.

The acquisition announcement does not provide new pivotal efficacy results demonstrating that D-Fi has satisfied the endpoints required for approval. The treatment’s commercial value therefore remains closely linked to the continuation and outcome of clinical development.

D-Fi enters a market where approved epidermolysis bullosa gene therapies already exist

The therapeutic opportunity must be considered alongside existing treatment options rather than as an entirely unserved market.

Krystal Biotech’s Vyjuvek received FDA approval in May 2023 for wounds associated with dystrophic epidermolysis bullosa. The product is a topical gene therapy designed to deliver a functional COL7A1 gene to affected tissue, with the approved indication subsequently expanded.

Abeona Therapeutics also obtained FDA approval in April 2025 for Zevaskyn, an autologous cell sheet-based gene therapy for wounds in patients with recessive dystrophic epidermolysis bullosa.

These approvals demonstrate that advanced therapies have entered the market, while also establishing meaningful competition for additional products seeking regulatory clearance.

D-Fi employs a distinct approach based on genetically modified fibroblasts administered through local injection. Its potential differentiation may involve administration characteristics, repeat dosing, treatment durability, the types of wounds addressed and practical delivery considerations.

However, differences in technology do not establish superior clinical effectiveness. Comparisons with existing approved treatments would require appropriate evidence, including consideration of patient populations, trial designs and measured outcomes.

Manufacturing and treatment logistics will also affect competitiveness. Autologous cell therapies require patient-specific processes, creating potential operational demands involving cell collection, manufacturing, quality control and treatment scheduling.

The product’s economic proposition would need to account for these requirements alongside clinical outcomes and reimbursement arrangements.

Castle Creek has identified potential future applications for its fibroblast platform, including a topical D-Fi formulation and research involving other serious skin conditions. Those programmes remain development opportunities rather than approved products or established revenue sources.

How does the merger change Pelthos Therapeutics’ existing dermatology business?

Pelthos entered the transaction with an established commercial product and additional approved dermatology assets.

Its principal marketed medicine is Zelsuvmi, a topical berdazimer gel used to treat molluscum contagiosum in adults and children aged one year and older. The company launched the product commercially in July 2025.

During the second quarter of 2026, Zelsuvmi generated $15.4 million in net product revenue, an increase of approximately 45% from $10.7 million in the preceding quarter.

Pelthos reported that 11,925 units were dispensed during the second quarter, compared with 8,084 in the first quarter. More than 25,000 patients had received prescriptions during the product’s first four quarters of commercial availability.

The company has also expanded access through insurance formularies. An October 6 announcement reported commercial formulary coverage reaching approximately 127 million covered lives, equivalent to 69% of the commercial market identified by Pelthos.

These achievements indicate progress in building an existing revenue-generating dermatology business. However, insurance coverage does not automatically translate into prescriptions, completed treatments or revenue at a predictable rate.

Pelthos also holds approved dermatology products Xepi and Xeglyze. At its August financial update, management planned commercial introductions during the first and third quarters of 2027, respectively.

The Castle Creek merger would therefore combine products at different stages of commercial maturity. Zelsuvmi provides an existing source of pharmaceutical revenue, while Xepi and Xeglyze represent planned commercial opportunities and D-Fi remains dependent on clinical and regulatory development.

This portfolio may broaden the company’s potential revenue base over time, but it also introduces competition for management attention and capital.

Why does Pelthos’ existing financial position make the merger financing important?

Pelthos’ latest reported quarterly results show a growing commercial business that had not yet achieved profitability.

The company reported a second-quarter 2026 net loss of $23.4 million, compared with $25.1 million in the first quarter. Adjusted EBITDA remained negative at $5.7 million, although this represented an improvement from the preceding quarter.

Selling, general and administrative expenditure reached $27.7 million in the second quarter, compared with $21.1 million in the first. Management attributed part of the increase to royalty and milestone costs, including non-recurring sales-related obligations.

At June 30, Pelthos held approximately $24.2 million in cash and cash equivalents. Its balance sheet also included liabilities associated with debt and other financing arrangements.

Those figures predate the October financing amendments and should not be treated as the company’s current cash or debt position.

The October 30 regulatory filing establishes that Pelthos amended its existing Horizon Technology Finance loan agreement. An additional $10 million in term loans was funded, increasing outstanding principal under the amended facility to $40 million.

The amended agreement also provides for up to another $10 million of potential borrowing, subject to lender discretion and specified requirements, including a trailing twelve-month net revenue threshold of at least $70 million.

This remaining amount is not committed cash already received.

The outstanding loans bear floating interest based on the prime rate plus 3.75 percentage points, subject to a contractual prime-rate floor. The facility matures in January 2031, with amortisation arrangements that depend partly on specified revenue milestones.

The larger financial picture includes existing revenue from Zelsuvmi, ongoing commercial expenses, future product launch requirements and the additional development spending that could follow the merger.

The planned private financing may provide resources for these activities, but the net liquidity benefit will depend on how much cash is actually contributed after accounting for note cancellations, debt repayments and transaction costs.

Why did PTHS shares fall sharply after the October 30 merger announcement?

Pelthos Therapeutics shares were trading at approximately $11.11 at 10:55 a.m. Eastern Time on October 30, representing a decline of 32.84% from the previous closing price of $16.54.

The quoted equity market capitalisation at that point was approximately $42.5 million, based on the market data provider’s reported common share count.

The share-price decline coincided with disclosure of the proposed Castle Creek merger, preferred financing and potentially substantial future share issuances. The announcement introduced several new variables affecting the company’s future ownership and financial structure.

However, daily market movements can also reflect liquidity, broader biotechnology sector conditions and trading dynamics. The available evidence does not establish a single definitive cause for the decline.

The stock had already experienced substantial weakness before the announcement. As of October 29, Pelthos shares were down approximately 21% over the preceding month, although they had recovered during the two immediately preceding sessions.

The October 30 trading response suggests a cautious market assessment of the enlarged transaction structure, but price changes alone cannot establish which specific elements investors consider most consequential.

The potential issuance of additional ordinary shares is one consideration. Future ownership could also be affected by preferred conversions, warrant exercise and contingent acquisition consideration, making a simple comparison between the current share price and the headline value of Castle Creek insufficient.

Broker price targets published before the transaction may also reflect assumptions about a materially different corporate and capital structure. The merger’s financing arrangements and clinical pipeline expansion will require updated financial models before those targets can be compared meaningfully with the post-announcement business.

The most useful valuation analysis will emerge when Pelthos provides pro forma share counts, projected liquidity and a development spending plan reflecting the proposed combination.

What milestones will determine whether the Castle Creek merger creates lasting value for Pelthos shareholders?

The first milestone is transaction completion, currently expected by the end of March 2027. Castle Creek shareholder approval, applicable securities filings, regulatory requirements and completion of the planned financing remain relevant conditions.

The financing terms will also require careful assessment once completed. Investors will need to distinguish newly received cash from the conversion or cancellation of existing obligations and understand how preferred share issuance changes the potential equity base.

Clinical development presents a longer-term test.

D-Fi must demonstrate appropriate efficacy and safety in its continuing development programme before it can seek or obtain the required marketing approval. Successful completion of specified clinical milestones could also trigger acquisition consideration, meaning positive development outcomes may be accompanied by additional financial obligations.

Commercial execution provides another test. Pelthos will need to maintain the growth of Zelsuvmi while preparing its other approved products for commercial introduction and supporting Castle Creek’s clinical programme.

The combined business could benefit from existing dermatology relationships and a broader product portfolio. However, commercial experience in topical dermatology medicines does not automatically resolve the specialised manufacturing and treatment requirements associated with autologous gene-modified cell therapy.

Management will also need to explain how the proposed acquisition affects future operating expenditure and financing requirements.

Pelthos is attempting to expand from a commercial dermatology platform into a business with both marketed medicines and late-stage advanced therapies. The transaction creates potential clinical and commercial opportunities, but these must be weighed against contingent consideration, financing costs and the possibility of a substantially larger diluted share count.

The decisive evidence will come from a completed and transparently financed merger, progress in D-Fi’s Phase 3 programme and sustained growth in the existing pharmaceutical business. Those outcomes will determine whether the new asset adds economic value sufficient to compensate shareholders for the capital and ownership committed to acquiring it.

Key takeaways from the Pelthos Therapeutics and Castle Creek Biosciences merger

• Pelthos Therapeutics announced a definitive agreement on October 30, 2026, to combine with Castle Creek Biosciences, expanding its dermatology portfolio into gene-modified cell therapy.
• Castle Creek shareholders are expected to receive 5.2 million Pelthos common shares at closing, representing approximately 32.5% of the specified pre-financing fully diluted share base.
• An additional 5.8 million shares may become payable following FDA approval of D-Fi, subject to contractual timing and other conditions.
• Castle Creek shareholders may also receive up to $300 million in milestone payments tied to clinical progress, first commercial sale and specified future sales thresholds.
• The merger is accompanied by a proposed private financing of at least $57.5 million, with a potential maximum of $80 million including bridge financing.
• Pelthos has increased outstanding term loan principal under its amended Horizon Technology Finance facility to $40 million, with further borrowing remaining conditional.
• D-Fi is an investigational treatment for dystrophic epidermolysis bullosa and has not received FDA marketing approval.
• Existing approved therapies from Krystal Biotech and Abeona Therapeutics create a competitive environment for additional epidermolysis bullosa treatments.
• Pelthos reported $15.4 million in second-quarter Zelsuvmi sales and a $23.4 million quarterly net loss, indicating commercial growth alongside continuing financial requirements.
• PTHS shares were quoted approximately 33% below the previous close during October 30 trading, while future shareholder value will depend on deal completion, financing terms and clinical execution.